Prevalência, aspectos clínicos e tratamento da depressão na doença de parkinson
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar a prevalência da depressão em pacientes com doença de Parkinson, identificar os aspectos clínicos da depressão nessa população e analisar as opções de tratamentos disponíveis. Métodos: Por meio da plataforma de dados Pubmed, foi realizada uma revisão integrativa da literatura, com o intento de localizar fontes relevantes para tal. Foram utilizados os termos de pesquisa: Depression; Depressive Disorder; e Parkinson Disease, associados com operadores booleanos na seguinte estratégia de pesquisa: ((Depression) OR ("Depressive Disorder"[MeSH])) AND ("Parkinson Disease"[MeSH]), resultando em 1241 artigos iniciais. Dentro destes, apenas 22 artigos tornam-se fontes oficiais, conforme critérios de inclusão e exclusão. Resultados: Os estudos mostraram forte relação entre a Doença de Parkinson e a Depressão mesmo que subdiagnosticada e, consequentemente pior impacto na funcionalidade física, ainda com lacunas quanto à melhor terapêutica para estes pacientes. Considerações finais: Pacientes com Doença de Parkinson e Depressão concomitantes, têm piora na qualidade de vida e nos sintomas motores.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ANZALDI K e SHIFREN K. Optimism, Pessimism, Coping, and Depression: A Study on Individuals with Parkinson's Disease. The International Journal of Aging and Human Development, 2018; 88(3), 231-249.
3. CHEN J, et al. Non-pharmacological treatment for Parkinson disease patients with depression: a meta-analysis of repetitive transcranial magnetic stimulation and cognitive-behavioral treatment. International Journal of Neuroscience, 2021;131 (4):411-424.
4. CONG S, et al. Prevalence and Clinical aspects of Depression in Parkinson's Disease: A systematic review and meta-analysis of 129 studies. Neuroscience and Biobehavioral Reviews, 2022; 141: 1-7.
5. CRIPPA JAS, et al. Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?. European archives of psychiatry and clinical neuroscience, 2019; 269:121-133.
6. HONG CT et al. Psychotherapy for the Treatment of Anxiety and Depression in Patients with Parkinson Disease: A Meta-Analysis of Randomized Controlled Trials. Journal of the American Medical Directors Association, 2021; 22(11): 2289-2295.e2.
7. DEMARCO EC, et al.Exploring treatment for depression in Parkinson’s patients: a cross-sectional analysis. International journal of environmental research and public health, 2021;18 (16): 8596.
8. GALTS CPC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019; 102: 56-84.
9. HAI-JIAO W, et al. The efficacy of repetitive transcranial magnetic stimulation for Parkinson disease patients with depression. International Journal of Neuroscience, 2020; 130(1): 19-27.
10. HAN JW, et al. Psychiatric manifestation in patients with Parkinson's disease. Journal of Korean medical science,2018; 33(47): 1-17.
11. JENNER P, et al. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson’s disease? Parkinsonism & Related Disorders, 2020; 80(1): S28-S36.
12. KWOK JYY, et al. Efeitos do mindfulness yoga versus exercícios de alongamento e treinamento de resistência na ansiedade e depressão para pessoas com doença de Parkinson: um ensaio clínico randomizado. JAMA neurology ,2019; 76(7): 755-763.
13. LEE Y, et al. The presence of depression in de novo Parkinson's disease reflects poor motor compensation. PLoS One. 2018; 13(9): e0203303.
14. PATTERSON L, et al. Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders. Brain Pathology, 2019; 29(4): 544-557.
15. PONTONE GM e MILLS KA. Optimal Treatment of Depression and Anxiety in Parkinson's Disease. Am J Geriatr Psychiatry. 2021; 29(6): 530-540.
16. PRANGE S, et al. Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment, 2022; 39(6), 417-439.
17. RYAN M, et al.Drug treatment strategies for depression in Parkinson disease. Expert opinion on pharmacotherapy, 2019; 20(11), 1351-1363.
18. SANTOS‐GARCÍA D, et al. Mood in Parkinson's disease: from early‐to late‐stage disease. International journal of geriatric psychiatry, 2021; 36(5): 627-646.
19. SHEN Q, et al. Impaired white matter microstructure associated with severe depressive symptoms in patients with PD. Brain Imaging and Behavior, 2022; 16: 169–175.
20. SU W, et al. Correlation between depression and quality of life in patients with Parkinson’s disease. Elsevier BV, Clinical Neurology And Neurosurgery, 2021; 202: e106523.
21. TAKAHASHI M, et al. Antidepressants for Depression, Apathy, and Gait Instability in Parkinson’s Disease: A Multicenter Randomized Study. Intern Med Advance Publication, 2018; 58(3): 361-368.
22. WEINTRAUB D e MAMIKONYAN E. The neuropsychiatry of Parkinson disease: a perfect storm. The American Journal of Geriatric Psychiatry, 2019; 27(9): 998-1018.